Actively Recruiting
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2025-09-30
150
Participants Needed
1
Research Sites
67 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective is to evaluate the tolerance, safety, pharmacokinetic characteristics and immunogenicity of SHR-A1811 combined with carboplatin and bevacizumab in the treatment of platinum sensitive recurrent epithelial ovarian cancer, and to determine the RP2D of the combination, and preliminarily to evaluate the effectiveness of SHR-A1811 combined regimen in the treatment of platinum sensitive recurrent epithelial ovarian cancer.
CONDITIONS
Official Title
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily join this study, sign the informed consent form, have good compliance, and can cooperate with the follow-up.
- Provide sufficient fresh or archived tumor tissue specimens for testing.
- Have at least one measurable lesion conforming to RECIST v1.1.
- Have an ECOG performance status score of 0 or 1.
- Expected survival of at least 12 weeks.
- Female participants with fertility must agree to follow contraceptive requirements from consent signing until 7 months after last trial drug administration.
You will not qualify if you...
- Have untreated or active central nervous system tumor metastasis, including meningeal metastasis.
- Have pleural, pericardial, or peritoneal effusions with symptoms that cannot be controlled.
- History of interstitial pneumonia, interstitial lung disease, or non-infectious pneumonia needing steroid treatment.
- Have hypertension that cannot be controlled by medication.
- Have poorly controlled or serious cardiovascular diseases.
- Have had a serious infection within 1 month before starting medication.
- History of immune deficiency including HIV positive status, other acquired or congenital immune deficiencies, or organ transplantation.
- Any other factors that may affect study results or cause early study termination such as alcohol or drug abuse, criminal detention, or serious diseases including mental illness requiring treatment.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430000
Actively Recruiting
Research Team
S
Shuni Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here